The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio
Expert Testimony - Celgene; sanofi
 
David C. Smith
Research Funding - Agensys (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Regeneron (Inst); Seagen (Inst); Takeda (Inst); Tekmira (Inst); Teva (Inst)
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Honoraria - BN ImmunoTherapeutics; GTx
Consulting or Advisory Role - GTX
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Cougar Biotechnology; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
Travel, Accommodations, Expenses - Bavarian Nordic; GTx
 
Jingsong Zhang
Honoraria - AstraZeneca; Bayer; Sanofi
Consulting or Advisory Role - Bayer; Sanofi
Speakers' Bureau - AstraZeneca; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst)
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca; Janssen (Inst); Merck (Inst); Pfizer; Roche (Inst)
 
Joseph D. Ruether
Speakers' Bureau - Astellas Pharma; Novartis
Research Funding - Astellas Pharma
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Acceleron Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Horizon Pharma; Inovio Pharmaceuticals; Lilly; Novartis; Pfizer
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
Jaime R. Merchan
Consulting or Advisory Role - Exelixis
Research Funding - Agensys; Lilly; Novartis; Rexahn Pharmaceuticals; Tocagen; TRACON Pharma
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; Novartis; pfizer
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Joaquina Celebre Baranda
Employment - Halozyme
Research Funding - Novartis
 
Joshua Michael Lang
Stock and Other Ownership Interests - Salus Discovery
Consulting or Advisory Role - Sanofi; Sanofi
Research Funding - Agensys (Inst); Medivation (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Matthew I. Milowsky
Research Funding - Acerta Pharma (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Incyte (Inst); Innocrin Pharma (Inst); Inovio Pharmaceuticals (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); X4 Pharma (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Alexander I. Spira
Honoraria - ARIAD; Clovis Oncology; Novartis; Roche
Consulting or Advisory Role - ARIAD; Clovis Oncology; Roche/Genentech
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Ignyta (Inst); Incyte (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ARIAD; Clovis Oncology; Roche
 
Elaina M. Gartner
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Research Funding - Agensys; Astellas Pharma; Seagen
Travel, Accommodations, Expenses - Seagen
 
Chunzhang Wu
Employment - Astellas Pharma
 
Amal Melhem-Bertrandt
Employment - Astellas Pharma
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EMD Serono; Inovio Pharmaceuticals; Lilly; Merck; Oncogenex; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche